177 related articles for article (PubMed ID: 19998405)
21. Knockout of tissue transglutaminase ameliorates TGFβ2-induced ocular hypertension: A novel therapeutic target for glaucoma?
Raychaudhuri U; Millar JC; Clark AF
Exp Eye Res; 2018 Jun; 171():106-110. PubMed ID: 29535003
[TBL] [Abstract][Full Text] [Related]
22. Kaempferol induces ROS-dependent apoptosis in pancreatic cancer cells via TGM2-mediated Akt/mTOR signaling.
Wang F; Wang L; Qu C; Chen L; Geng Y; Cheng C; Yu S; Wang D; Yang L; Meng Z; Chen Z
BMC Cancer; 2021 Apr; 21(1):396. PubMed ID: 33845796
[TBL] [Abstract][Full Text] [Related]
23. Organization and chromosomal mapping of mouse Gh/tissue transglutaminase gene (Tgm2).
Nanda N; Iismaa SE; Copeland NG; Gilbert DJ; Jenkins N; Graham RM; Sutrave P
Arch Biochem Biophys; 1999 Jun; 366(1):151-6. PubMed ID: 10334875
[TBL] [Abstract][Full Text] [Related]
24. Targeting transglutaminase 2 partially restores extracellular matrix structure but not alveolar architecture in experimental bronchopulmonary dysplasia.
Mižíková I; Pfeffer T; Nardiello C; Surate Solaligue DE; Steenbock H; Tatsukawa H; Silva DM; Vadász I; Herold S; Pease RJ; Iismaa SE; Hitomi K; Seeger W; Brinckmann J; Morty RE
FEBS J; 2018 Aug; 285(16):3056-3076. PubMed ID: 29935061
[TBL] [Abstract][Full Text] [Related]
25. Cinnamoyl inhibitors of tissue transglutaminase.
Pardin C; Pelletier JN; Lubell WD; Keillor JW
J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
[TBL] [Abstract][Full Text] [Related]
26. Transglutaminase activity as a possible therapeutical target in neurodegenerative diseases.
Iannaccone M; Titta F; Serretiello E; De Vivo G; Martin A; Gentile V
Recent Pat CNS Drug Discov; 2013 Dec; 8(3):235-42. PubMed ID: 24286449
[TBL] [Abstract][Full Text] [Related]
27. Transglutaminase 2 Inhibition Reverses Mesenchymal Transdifferentiation of Glioma Stem Cells by Regulating C/EBPβ Signaling.
Yin J; Oh YT; Kim JY; Kim SS; Choi E; Kim TH; Hong JH; Chang N; Cho HJ; Sa JK; Kim JC; Kwon HJ; Park S; Lin W; Nakano I; Gwak HS; Yoo H; Lee SH; Lee J; Kim JH; Kim SY; Nam DH; Park MJ; Park JB
Cancer Res; 2017 Sep; 77(18):4973-4984. PubMed ID: 28754668
[TBL] [Abstract][Full Text] [Related]
28. Recent Progress in the Development of Transglutaminase 2 (TGase2) Inhibitors.
Song M; Hwang H; Im CY; Kim SY
J Med Chem; 2017 Jan; 60(2):554-567. PubMed ID: 28122456
[TBL] [Abstract][Full Text] [Related]
29. Transglutaminase 2, a novel regulator of eicosanoid production in asthma revealed by genome-wide expression profiling of distinct asthma phenotypes.
Hallstrand TS; Wurfel MM; Lai Y; Ni Z; Gelb MH; Altemeier WA; Beyer RP; Aitken ML; Henderson WR
PLoS One; 2010 Jan; 5(1):e8583. PubMed ID: 20052409
[TBL] [Abstract][Full Text] [Related]
30. Tissue Transglutaminase Elevates Intraocular Pressure in Mice.
Raychaudhuri U; Millar JC; Clark AF
Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6197-6211. PubMed ID: 29222550
[TBL] [Abstract][Full Text] [Related]
31. Acyl transfer mechanisms of tissue transglutaminase.
Keillor JW; Clouthier CM; Apperley KYP; Akbar A; Mulani A
Bioorg Chem; 2014 Dec; 57():186-197. PubMed ID: 25035302
[TBL] [Abstract][Full Text] [Related]
32. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer.
Park KS; Kim HK; Lee JH; Choi YB; Park SY; Yang SH; Kim SY; Hong KM
J Cancer Res Clin Oncol; 2010 Apr; 136(4):493-502. PubMed ID: 19763620
[TBL] [Abstract][Full Text] [Related]
33. Reaction of human albumin with aspirin in vitro: mass spectrometric identification of acetylated lysines 199, 402, 519, and 545.
Liyasova MS; Schopfer LM; Lockridge O
Biochem Pharmacol; 2010 Mar; 79(5):784-91. PubMed ID: 19836360
[TBL] [Abstract][Full Text] [Related]
34. Potential of transglutaminase 2 as a therapeutic target.
Caccamo D; Currò M; Ientile R
Expert Opin Ther Targets; 2010 Sep; 14(9):989-1003. PubMed ID: 20670177
[TBL] [Abstract][Full Text] [Related]
35. Tissue transglutaminase in Alzheimer's disease: involvement in pathogenesis and its potential as a therapeutic target.
Wilhelmus MM; de Jager M; Bakker EN; Drukarch B
J Alzheimers Dis; 2014; 42 Suppl 3():S289-303. PubMed ID: 24685636
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma.
Erdem M; Erdem S; Sanli O; Sak H; Kilicaslan I; Sahin F; Telci D
Urol Oncol; 2014 Jan; 32(1):25.e13-20. PubMed ID: 23499501
[TBL] [Abstract][Full Text] [Related]
37. Possible physiopathological roles of the transglutaminase activity in the etiopathogenesis of human neurodegenerative diseases.
Titta F; Iannaccone M; Martin A; Gentile V
Recent Pat CNS Drug Discov; 2014; 9(2):101-9. PubMed ID: 24924102
[TBL] [Abstract][Full Text] [Related]
38. Tissue transglutaminase is involved in mechanical load-induced osteogenic differentiation of human ligamentum flavum cells.
Chao YH; Huang SY; Yang RC; Sun JS
Connect Tissue Res; 2016 Jul; 57(4):307-18. PubMed ID: 27115725
[TBL] [Abstract][Full Text] [Related]
39. Transglutaminase activity regulates atherosclerotic plaque composition at locations exposed to oscillatory shear stress.
Matlung HL; Neele AE; Groen HC; van Gaalen K; Tuna BG; van Weert A; de Vos J; Wentzel JJ; Hoogenboezem M; van Buul JD; VanBavel E; Bakker EN
Atherosclerosis; 2012 Oct; 224(2):355-62. PubMed ID: 22921425
[TBL] [Abstract][Full Text] [Related]
40. Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative Pathologies by Impeding Protein Aggregation.
Ayyadevara S; Balasubramaniam M; Kakraba S; Alla R; Mehta JL; Shmookler Reis RJ
Antioxid Redox Signal; 2017 Dec; 27(17):1383-1396. PubMed ID: 28537433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
